A61K35/12

METHOD FOR MANUFACTURING MITOCHONDRIA-RICH PLASMA

The embodiments of the present disclosure provide a manufacturing method of mitochondria-rich plasma. The mitochondria-rich plasma can increase the cell viability of damaged cells, decrease the cellular senescence level, repair the oxidative damage of cells, and relieve the inflammation of hair follicles so as to achieve the purpose of promoting hair regrowth.

ANTI-TRANSFERRIN EXTRACELLULAR VESICLES

The present disclosure relates extracellular vesicles, e.g., exosomes, comprising an antigen-binding moeity, e.g., a single-domain antigen-binding moeity, e.g., a vNAR, a VHH, or a fragment thereof, that specifically binds transferrin receptor, and methods of making and using the same.

RAPID VACCINE PLATFORM
20230218733 · 2023-07-13 ·

Provided are methods of making and delivering vaccine compositions using an enucleated cell-based platform. Methods of clearing pathogenic infections in a subject using the enucleated cell-based platform is also provided. Such enucleated cell-based platform reduces the vaccine development timeline as compared with conventional biological vaccines, and improves vaccine efficacy.

Compositions containing exosome carrying NF-κB inhibitors and methods of using thereof

The present invention is related to compositions containing extracellular vesicles (exosomes) and methods of using the same for increasing lifespan of fetus, viability of fetus, or viability of newborn, for treating inflammation in uterus and/or fetus, for delaying preterm birth, or for treating a condition related to inflammation in uterus and/or fetus, wherein the extracellular vesicles comprising a nuclear factor kappa beta (NF-κB) inhibitor and a photo-specific binding protein.

Production Device, Production System and Production Method for Cell Structure
20230212490 · 2023-07-06 ·

Provided are: a production device by which a cell structure having a three-dimensional structure is produced using a plurality of linear members; a production system therefor; and a production method therefor. The production device 100 comprises a top plate 110, pins 120A to 120D, a first slide plate 130, a second slide plate 140, a stopper 150, a base plate 160, an outer peripheral needle-shaped member 170 and an inner peripheral needle-shaped member 180. Cell aggregates 400 are put into a three-dimensional tubular space S1 that is defined by the outer peripheral needle-shaped member 170 and the inner peripheral needle-shaped member 180. Then, the top plate 110 is pressed downward on the accumulated cell aggregates 400. Thus, the cell aggregates 400 are immersed in a culture solution 210 and stuck together so that a tubular cell structure 500 is produced using the three-dimensional space S1 as a mold.

PLATFORM FOR GENERATING SAFE CELL THERAPEUTICS
20230212520 · 2023-07-06 ·

Provided herein are cytoplasts, compositions comprising cytoplasts, methods of using cytoplasts, and methods of treating a subject, such as providing benefits to a healthy or unhealthy subject, or treating or diagnosing a disease or condition in a subject. In some embodiments, methods of treating a subject include: administering to the subject a therapeutically effective amount of a composition comprising a cytoplast. Also, provided herein are compositions (e.g., pharmaceutical compositions) that include a cytoplast. Also, provided herein are kits comprising instructions for using the compositions or methods.

Methods and products to provide oral nutritional care to subjects with dementia
11547136 · 2023-01-10 · ·

The present invention provides food products, nutritional programs, and methods for meeting nutritional needs of subjects with dementia and related cognitive disorders. In one embodiment, the invention provides a food product comprising a reversibly sealed container and a soup, wherein the soup is in the container and comprises a total volume of 200-2000 mls, a vegetable or meat component, 300 to 2500 calories, a macronutrient caloric distribution comprising: 20-80% fat, 10-45% protein, and 10-65% carbohydrate, about 2% to about 40% medium chain triglycerides, omega 3 fatty acids in an amount of 100 to 2000 mg and less than 20 solid food particles having a volume greater than about 20 cm.sup.3. Such food products, when administered to affected subjects, can positively impact (i) nutritional status; (ii) quality of life; (iii) disease course; (v) the demand for assistance from a care giver; (vi) subject compliance with a nutritional plan using the food product, and (vii) ease of monitoring compliance by the caregiver for verification.

Methods and products to provide oral nutritional care to subjects with dementia
11547136 · 2023-01-10 · ·

The present invention provides food products, nutritional programs, and methods for meeting nutritional needs of subjects with dementia and related cognitive disorders. In one embodiment, the invention provides a food product comprising a reversibly sealed container and a soup, wherein the soup is in the container and comprises a total volume of 200-2000 mls, a vegetable or meat component, 300 to 2500 calories, a macronutrient caloric distribution comprising: 20-80% fat, 10-45% protein, and 10-65% carbohydrate, about 2% to about 40% medium chain triglycerides, omega 3 fatty acids in an amount of 100 to 2000 mg and less than 20 solid food particles having a volume greater than about 20 cm.sup.3. Such food products, when administered to affected subjects, can positively impact (i) nutritional status; (ii) quality of life; (iii) disease course; (v) the demand for assistance from a care giver; (vi) subject compliance with a nutritional plan using the food product, and (vii) ease of monitoring compliance by the caregiver for verification.

KOC1-derived peptide and vaccine including same

The present invention provides KOC1-derived epitope peptides having the ability to induce cytotoxic T cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic T cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or CTLs. The present invention also provides compositions and pharmaceutical compositions containing them as an active ingredient. Further, the present invention provides methods of treating and/or preventing cancer, and/or preventing postoperative recurrence thereof, using the peptides, polynucleotides, antigen-presenting cells, cytotoxic T cells or pharmaceutical compositions of the present invention. Methods of inducing an immune response against cancer are also provided.

KOC1-derived peptide and vaccine including same

The present invention provides KOC1-derived epitope peptides having the ability to induce cytotoxic T cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic T cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or CTLs. The present invention also provides compositions and pharmaceutical compositions containing them as an active ingredient. Further, the present invention provides methods of treating and/or preventing cancer, and/or preventing postoperative recurrence thereof, using the peptides, polynucleotides, antigen-presenting cells, cytotoxic T cells or pharmaceutical compositions of the present invention. Methods of inducing an immune response against cancer are also provided.